Murley, Chantelle http://orcid.org/0000-0003-4150-4275
Tinghög, Petter http://orcid.org/0000-0001-6138-6427
Alexanderson, Kristina http://orcid.org/0000-0002-9313-3413
Hillert, Jan http://orcid.org/0000-0002-7386-6732
Friberg, Emilie http://orcid.org/0000-0001-7874-4243
Karampampa, Korinna http://orcid.org/0000-0002-2578-1865
Funding for this research was provided by:
Biogen (4-2803/2019)
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (2007-1762)
Karolinska Institute
Article History
Accepted: 18 April 2021
First Online: 10 May 2021
Change Date: 24 October 2021
Change Type: Update
Change Details: The Funding note is included and deleted from the Declarations section.
Declarations
:
: Chantelle Murley, Kristina Alexanderson, and Emilie Friberg were partly funded by an unrestricted research grant from Biogen. Kristina Alexanderson has received unrestricted researcher-initiated grants from Biogen. Emilie Friberg has received unrestricted researcher-initiated grants from Celgene. Petter Tinghög has previously received salaries partly funded by Biogen and has no conflicts of interest directly relevant to the content of this article. Korinna Karampampa has previously been employed and received salaries from Karolinska Institutet that were partly funded by Biogen, but not for conducting this study and has not received any salary from Karolinska Institutet or Biogen since October 2019. Currently Korinna Karampampa is only affiliated with Karolinska Institutet, not receiving any financial compensation for her involvement in this study. Korinna Karampampa is working full time at a biopharmaceutical company, Gilead Sciences AB. Jan Hillert received honoraria for serving on advisory boards for Biogen and Novartis and speaker’s fees from Biogen, Merck-Serono, Bayer-Schering, Teva and Sanofi-Aventis. He has served as the principal investigator for projects sponsored by, or received unrestricted research support from, Biogen, Merck-Serono, TEVA, Novartis and Bayer-Schering. Jan Hillert’s MS research is also funded by the Swedish Research Council.
: Approval for the research project was obtained from the Regional Ethical Review Board in Stockholm, Dnrs: 2007/762-31; 2009/23-32; 2009/1917-32; 2010/466-32; 2011/806-32; 2011/1710-32; and 2014/236-32. The study was performed in accordance with the tenants of the Declaration of Helsinki and later amendments. Informed consent from the research participants was not applicable owing to the use of pseudonymised data from total population administrative registers and that we do not hold individual details revealing the identity of the participants. Individuals included in the voluntary Swedish MS Registry provide consent for the neurologist to enter their information into the register for both clinical and research purposes.
: Not applicable.
: Not applicable.
: No data are available. Please contact Prof. Kristina Alexanderson (<u>kristina.alexanderson@ki.se</u>) about why the data, according to the General Data Protection Regulation, the Swedish Data Protection Act, the Swedish Ethical Review Act and the Swedish Public Access to Information and Secrecy Act, cannot be made available.
: Not applicable.
: All authors contributed to the study conception and design. Data for this study were obtained by KA and JH. Data management and analysis were performed by CM. Statistical interpretation was conducted by CM, PT, EF and KK. The first draft of the manuscript was written by CM and all authors commented on versions of the manuscript. All authors have read and approved the final manuscript.